Aspiring desensitization enabled dual antiplatelet therapy after PCI, but failed upon reattempt; switching to ticagrelor monotherapy provided safe effective treatment.
Does ticagrelor monotherapy prevent complications in a post-PCI patient with aspirin hypersensitivity who fails desensitization?
Ticagrelor monotherapy may serve as a safe and viable alternative strategy for post-PCI patients with aspirin hypersensitivity who fail desensitization protocols.
Absolute Event Rate: 0% vs 0%
ABSTRACT In managing atherosclerotic cardiovascular disease, especially after percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT), prominently aspirin and a P2Y12 inhibitor, is fundamental. Nonetheless, aspirin hypersensitivity complicates treatment for some patients. Desensitization processes have been identified as a viable method to circumvent this issue. This case report describes a 75‐year‐old man diagnosed with significant stenosis in the coronary artery who was scheduled for elective PCI of the right coronary artery. The patient's medical record noted a hypersensitivity to aspirin. Initially, the patient underwent successful desensitization to aspirin, allowing for treatment with aspirin and Clopidogrel. However, the need for another desensitization emerged months later, which unfortunately was unsuccessful. As a result, the patient's treatment was shifted to Ticagrelor monotherapy, a potent antiplatelet strategy, which was carried out without any complications during the follow‐up period.
Mohammadi et al. (Sun,) reported a other. Aspiring desensitization enabled dual antiplatelet therapy after PCI, but failed upon reattempt; switching to ticagrelor monotherapy provided safe effective treatment.